Clarus Therapeutics Holdings Overview

Clarus Therapeutics Holdings Research & Development

Research & Development expenses for CRXT.

Quarterly R&D Expenses

$1.23M

↑ 102.81% YoY

As of Jun 30, 2022

Annual R&D Expenses (TTM)

$5.13M

↑ 151.3% YoY

Trailing 12 months ending Jun 30, 2022

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin